Podcasts about advances in women's health

Guest: Sara Tolaney MD, MPH There are several new strategies that have been emerging to treat patients with HER2+ breast cancer, and here to walk us through those that were highlighted at the 2020 ASCO Annual Meeting is Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at the Harvard Medical School.

Host: Mario R. Nacinovich, Jr., MSc Guest: Sara Tolaney MD, MPH Triple-negative breast cancer comprises up to 20 percent of all breast cancer diagnoses, and unfortunately, survival for these patients has been more limited than in other subtypes of disease. That’s why improving outcomes for patients with triple-negative breast cancer has been the focus of recent studies—much like the one investigating eribulin and pembrolizumab that Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute, presented at the 2020 ASCO Annual Meeting.

Guest: Sara Tolaney MD, MPH What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting.

Host: Matt Birnholz, MD Guest: Slavica Janeva, MD Despite the increasing number of elderly patients diagnosed with breast cancer, few clinical trials focus on this age group. That’s why Dr. Slavica Janeva's team focused on the impacts of adjuvant chemotherapy on survival rates in this patient population, the results of which may change clinical practice paradigms moving forward, as he discusses with Dr. Matt Birnholz.

Host: Matt Birnholz, MD Guest: Slavica Janeva, MD Despite the increasing number of elderly patients diagnosed with breast cancer, few clinical trials focus on this age group. That’s why Dr. Slavica Janeva's team focused on the impacts of adjuvant chemotherapy on survival rates in this patient population, the results of which may change clinical practice paradigms moving forward, as he discusses with Dr. Matt Birnholz.

Host: Matt Birnholz, MD Guest: Luka Dobovisek, MD Though cannabidiol (CBD) has long been recognized in the oncological field as a palliative therapeutic agent, only recently has it been demonstrated to induce anti-tumor responses in breast cancer. To learn more, Dr. Matt Birnholz is joined by Dr. Luka Dobovisek, whose recent study looked at the effect of CBD on cell viability of selected breast cancer cell lines, both as a single agent and in combinations with breast cancer therapies such as tamoxifen.

Host: Matt Birnholz, MD Guest: Luka Dobovisek, MD Though cannabidiol (CBD) has long been recognized in the oncological field as a palliative therapeutic agent, only recently has it been demonstrated to induce anti-tumor responses in breast cancer. To learn more, Dr. Matt Birnholz is joined by Dr. Luka Dobovisek, whose recent study looked at the effect of CBD on cell viability of selected breast cancer cell lines, both as a single agent and in combinations with breast cancer therapies such as tamoxifen.

Host: Matt Birnholz, MD Guest: Slavica Janeva, MD Despite the increasing number of elderly patients diagnosed with breast cancer, few clinical trials focus on this age group. That’s why Dr. Slavica Janeva's team focused on the impacts of adjuvant chemotherapy on survival rates in this patient population, the results of which may change clinical practice paradigms moving forward, as he discusses with Dr. Matt Birnholz.

Host: Paul Doghramji, MD Guest: Megan Arnot Menopause is an inevitable transition in every woman’s life, but what if engaging in a basic physiological need like sex could delay its onset? Researching this potential connection is Megan Arnot, a Ph.D. candidate in the Department of Anthropology at the University College London. As the lead author of the study, she walks us through her findings and the range of factors they investigated, like the type of sexual activity and whether or not women lived with a partner.

Host: Paul Doghramji, MD Guest: Megan Arnot Menopause is an inevitable transition in every woman’s life, but what if engaging in a basic physiological need like sex could delay its onset? Researching this potential connection is Megan Arnot, a Ph.D. candidate in the Department of Anthropology at the University College London. As the lead author of the study, she walks us through her findings and the range of factors they investigated, like the type of sexual activity and whether or not women lived with a partner.

Host: Paul Doghramji, MD Guest: Megan Arnot Menopause is an inevitable transition in every woman’s life, but what if engaging in a basic physiological need like sex could delay its onset? Researching this potential connection is Megan Arnot, a Ph.D. candidate in the Department of Anthropology at the University College London. As the lead author of the study, she walks us through her findings and the range of factors they investigated, like the type of sexual activity and whether or not women lived with a partner.

Host: Paul Doghramji, MD Guest: Megan Arnot Menopause is an inevitable transition in every woman’s life, but what if engaging in a basic physiological need like sex could delay its onset? Researching this potential connection is Megan Arnot, a Ph.D. candidate in the Department of Anthropology at the University College London. As the lead author of the study, she walks us through her findings and the range of factors they investigated, like the type of sexual activity and whether or not women lived with a partner.

Guest: C. Kent Osborne, MD After doing breast cancer research for over 40 years, Dr. Kent Osborne has seen a lot of advances in the field, and now he’s here to share his viewpoint on the opportunities and challenges that lie ahead.

Guest: C. Kent Osborne, MD After doing breast cancer research for over 40 years, Dr. Kent Osborne has seen a lot of advances in the field, and now he’s here to share his viewpoint on the opportunities and challenges that lie ahead.

Host: Matt Birnholz, MD Guest: Lauren Nye, MD Considering there’s little known about the breast microenvironment during pregnancy and whether this plays into future breast cancer risk, Dr. Lauren Nye's team examined whether omega 3 supplements as potential non-teratogenic chemoprevention agents could accentuate the protective changes on breast cancer risk that occur with hormonal fluctuations during pregnancy. And Dr. Matt Birnholz was there at the 2019 San Antonio Breast Cancer Symposium to catch up with Dr. Nye about this study.

Host: Matt Birnholz, MD Guest: Stephen Hiscox, PhD Though statins have long been used for the treatment of hypercholesterolemia, growing evidence suggests they may also have a role in lowering the risk of breast cancer development. But how they potentially do this and whether all statins are equal to that task was the focus of Dr. Matt Birnholz’s discussion with Dr. Stephen Hiscox at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Lauren Nye, MD Considering there’s little known about the breast microenvironment during pregnancy and whether this plays into future breast cancer risk, Dr. Lauren Nye's team examined whether omega 3 supplements as potential non-teratogenic chemoprevention agents could accentuate the protective changes on breast cancer risk that occur with hormonal fluctuations during pregnancy. And Dr. Matt Birnholz was there at the 2019 San Antonio Breast Cancer Symposium to catch up with Dr. Nye about this study.

Host: Matt Birnholz, MD Guest: Nadine Tung, MD Recorded live at the 2019 San Antonio Breast Cancer Symposium, Dr. Matt Birnholz sat down with Dr. Nadine Tung, Associate Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center, to talk about her presentation on genetic testing for hereditary breast cancer.

Host: Matt Birnholz, MD Guest: Marina Kaplan, PhD Ms. Marina Kaplan's inspiring life history as an "outlier survivor" as she put it for having achieved remission from triple-negative breast cancer over six years ago was helped by numerous cutting-edge clinical trials made accessible to her. But the experience as a study subject exposed her to systemic barriers confronting breast cancer patients everywhere, compelling her to reprise her epidemiology career expertise in conducting a study looking for novel solutions, as she shares with Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Daniela Rosa, MD To learn more about the effects of dietary interventions after early breast cancer treatment and the current gaps that exist in systemic reviews that assess those effects, Dr. Matt Birnholz sat down with Dr. Daniela Rosa at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Stephen Hiscox, PhD Though statins have long been used for the treatment of hypercholesterolemia, growing evidence suggests they may also have a role in lowering the risk of breast cancer development. But how they potentially do this and whether all statins are equal to that task was the focus of Dr. Matt Birnholz’s discussion with Dr. Stephen Hiscox at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Nadine Tung, MD Recorded live at the 2019 San Antonio Breast Cancer Symposium, Dr. Matt Birnholz sat down with Dr. Nadine Tung, Associate Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center, to talk about her presentation on genetic testing for hereditary breast cancer.

Host: Matt Birnholz, MD Guest: Lauren Nye, MD Considering there’s little known about the breast microenvironment during pregnancy and whether this plays into future breast cancer risk, Dr. Lauren Nye's team examined whether omega 3 supplements as potential non-teratogenic chemoprevention agents could accentuate the protective changes on breast cancer risk that occur with hormonal fluctuations during pregnancy. And Dr. Matt Birnholz was there at the 2019 San Antonio Breast Cancer Symposium to catch up with Dr. Nye about this study.

Host: Matt Birnholz, MD Guest: Nadine Tung, MD Recorded live at the 2019 San Antonio Breast Cancer Symposium, Dr. Matt Birnholz sat down with Dr. Nadine Tung, Associate Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center, to talk about her presentation on genetic testing for hereditary breast cancer.

Host: Matt Birnholz, MD Guest: Marina Kaplan, PhD Ms. Marina Kaplan's inspiring life history as an "outlier survivor" as she put it for having achieved remission from triple-negative breast cancer over six years ago was helped by numerous cutting-edge clinical trials made accessible to her. But the experience as a study subject exposed her to systemic barriers confronting breast cancer patients everywhere, compelling her to reprise her epidemiology career expertise in conducting a study looking for novel solutions, as she shares with Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Daniela Rosa, MD To learn more about the effects of dietary interventions after early breast cancer treatment and the current gaps that exist in systemic reviews that assess those effects, Dr. Matt Birnholz sat down with Dr. Daniela Rosa at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Daniela Rosa, MD To learn more about the effects of dietary interventions after early breast cancer treatment and the current gaps that exist in systemic reviews that assess those effects, Dr. Matt Birnholz sat down with Dr. Daniela Rosa at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Marina Kaplan, PhD Ms. Marina Kaplan's inspiring life history as an "outlier survivor" as she put it for having achieved remission from triple-negative breast cancer over six years ago was helped by numerous cutting-edge clinical trials made accessible to her. But the experience as a study subject exposed her to systemic barriers confronting breast cancer patients everywhere, compelling her to reprise her epidemiology career expertise in conducting a study looking for novel solutions, as she shares with Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Daniela Rosa, MD To learn more about the effects of dietary interventions after early breast cancer treatment and the current gaps that exist in systemic reviews that assess those effects, Dr. Matt Birnholz sat down with Dr. Daniela Rosa at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Stephen Hiscox, PhD Though statins have long been used for the treatment of hypercholesterolemia, growing evidence suggests they may also have a role in lowering the risk of breast cancer development. But how they potentially do this and whether all statins are equal to that task was the focus of Dr. Matt Birnholz’s discussion with Dr. Stephen Hiscox at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Jenn Simmons, MD Guest: Susan Domchek, MD Anytime the topic of genetic testing comes up in the context of breast and ovarian cancers, one question that undoubtedly arises is: who exactly should be tested? That’s the FAQ Dr. Susan Domchek, Director of the McDonald Women’s Cancer Risk Evaluation Center at the Hospital of the University of Pennsylvania, answers.

Host: Jenn Simmons, MD Guest: Susan Domchek, MD Anytime the topic of genetic testing comes up in the context of breast and ovarian cancers, one question that undoubtedly arises is: who exactly should be tested? That’s the FAQ Dr. Susan Domchek, Director of the McDonald Women’s Cancer Risk Evaluation Center at the Hospital of the University of Pennsylvania, answers.

Host: Matt Birnholz, MD Guest: Kelly Scheu, MS, NP At the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Matt Birnholz caught up with Kelly Scheu, a nurse practitioner specializing in breast oncology at the University of Michigan, who shared how her spirituality and medical expertise of 27 years in the oncology field blend to enhance breast cancer care.

Guest: Johnathan Strauss, MD Recorded live at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Jonathan Strauss, an Associate Professor of Radiation Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, shares key strategies for delivering targeted radiotherapy to avoid damaging associated tissues.

Guest: William J. Gradishar, MD Tune in to hear Dr. William Gradishar break down his presentations as well as other highlights attendees can look forward to at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois.

Guest: William J. Gradishar, MD Learn more about the mission of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium and the topics featured at the 2019 conference from Dr. William Gradishar, who’s served as the Chair of the Lynn Sage Breast Cancer Symposium since its inception in 1998.

Host: Matt Birnholz, MD Guest: Thanos Kosmidis Tune in as Dr. Matt Birnholz talks with Thanos Kosmidis, the founder and CEO of Care Across, about the company’s new poster presentation on breast cancer patients’ quality of life at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain.

Host: Matt Birnholz, MD Guest: Kelly Scheu, MS, NP At the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Matt Birnholz caught up with Kelly Scheu, a nurse practitioner specializing in breast oncology at the University of Michigan, who shared how her spirituality and medical expertise of 27 years in the oncology field blend to enhance breast cancer care.

Host: Matt Birnholz, MD Guest: Johnathan Strauss, MD Joining Dr. Matt Birnholz at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, is Dr. Jonathan Strauss to discuss the talks he’s given at this year’s conference on the evolution of radiation oncology as a field, challenging breast cancer cases, and emerging factors that support the emission of radiotherapy in invasive cancers.

Guest: Johnathan Strauss, MD Recorded live at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Jonathan Strauss, an Associate Professor of Radiation Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, shares key strategies for delivering targeted radiotherapy to avoid damaging associated tissues.

Guest: William J. Gradishar, MD Learn more about the mission of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium and the topics featured at the 2019 conference from Dr. William Gradishar, who’s served as the Chair of the Lynn Sage Breast Cancer Symposium since its inception in 1998.

Host: Matt Birnholz, MD Guest: Thanos Kosmidis Tune in as Dr. Matt Birnholz talks with Thanos Kosmidis, the founder and CEO of Care Across, about the company’s new poster presentation on breast cancer patients’ quality of life at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain.

Host: Matt Birnholz, MD Guest: Thanos Kosmidis Tune in as Dr. Matt Birnholz talks with Thanos Kosmidis, the founder and CEO of Care Across, about the company’s new poster presentation on breast cancer patients’ quality of life at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain.

Host: Matt Birnholz, MD Guest: Kelly Scheu, MS, NP At the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Matt Birnholz caught up with Kelly Scheu, a nurse practitioner specializing in breast oncology at the University of Michigan, who shared how her spirituality and medical expertise of 27 years in the oncology field blend to enhance breast cancer care.

Host: Matt Birnholz, MD Guest: Johnathan Strauss, MD Joining Dr. Matt Birnholz at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, is Dr. Jonathan Strauss to discuss the talks he’s given at this year’s conference on the evolution of radiation oncology as a field, challenging breast cancer cases, and emerging factors that support the emission of radiotherapy in invasive cancers.

Guest: William J. Gradishar, MD Tune in to hear Dr. William Gradishar break down his presentations as well as other highlights attendees can look forward to at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois.

Guest: Johnathan Strauss, MD Recorded live at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Jonathan Strauss, an Associate Professor of Radiation Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, shares key strategies for delivering targeted radiotherapy to avoid damaging associated tissues.